Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00321815 | Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer | PHASE2 | COMPLETED | 43 | — | — | Aug 1, 2006 | Jun 1, 2010 | Dec 23, 2010 | 35 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Standard of Care chemotherapy plus experimental intervention (PF-3512676) |
| B | ACTIVE_COMPARATOR | Standard of Care chemotherapy |
| Name | Type | Description |
|---|---|---|
| PF-3512676 + Erlotinib | DRUG | PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity. Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity |
| Erlotinib | DRUG | Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity |
Inclusion Criteria: * Advanced, EGFR-positive NSCLC * ECOG Performance Status 0, 1 or 2 * Measurable disease Exclusion Criteria: * Known CNS metastasis * Pre-existing autoimmune or antibody mediated disease